201 related articles for article (PubMed ID: 29185089)
1. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.
Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1777-1784. PubMed ID: 29959610
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
Sidhu MK; van Engen AK; Kleintjens J; Schoeman O; Palazzo M
Curr Med Res Opin; 2009 Aug; 25(8):2049-59. PubMed ID: 19575628
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.
Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
Mycoses; 2017 Nov; 60(11):714-722. PubMed ID: 28699297
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
[TBL] [Abstract][Full Text] [Related]
10. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
Wilke M
Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China.
Chen D; Wan X; Kruger E; Chen C; Yue X; Wang L; Wu J
J Med Econ; 2018 Mar; 21(3):301-307. PubMed ID: 29303621
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
Neoh CF; Liew D; Slavin M; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
J Antimicrob Chemother; 2011 Aug; 66(8):1906-15. PubMed ID: 21628305
[TBL] [Abstract][Full Text] [Related]
16. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
[TBL] [Abstract][Full Text] [Related]
17. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
[TBL] [Abstract][Full Text] [Related]
18. Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives.
Neoh CF; Slavin M; Chen SC; Stewart K; Kong DC
Int J Antimicrob Agents; 2014 Mar; 43(3):207-14. PubMed ID: 24670423
[TBL] [Abstract][Full Text] [Related]
19. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.
Zilberberg MD; Kothari S; Shorr AF
Crit Care; 2009; 13(3):R94. PubMed ID: 19545361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
